Literature DB >> 20498257

A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice.

Andreas Wieser1, Eva Romann, Giuseppe Magistro, Christiane Hoffmann, Dominik Nörenberg, Kirsten Weinert, Sören Schubert.   

Abstract

Infections due to extraintestinal pathogenic Escherichia coli (ExPEC) are common in humans and animals and include urinary tract infections (from uropathogenic E. coli [UPEC]), septicemia, and wound infections. These infections result in significant morbidity and mortality and in high health care costs. In view of the increasing number of ExPEC infections and the ever-growing antibiotic resistance capability of ExPEC isolates, preventive measures such as an effective vaccine against ExPEC are desirable. An ExPEC vaccine may be cost-effective for select patient groups. Previous vaccine candidates consisted of single target proteins or whole ExPEC cells. Here we describe a subunit vaccine against ExPEC which is based on immunodominant epitopes of the virulence-associated ExPEC proteins FyuA, IroN, ChuA, IreA, Iha, and Usp. Using a novel approach of computer-aided design, two completely artificial genes were created, both encoding eight peptide domains derived from these ExPEC proteins. The recombinant expression of these two genes resulted in a protein vaccine directed against ExPEC but not against commensal E. coli of the gut flora. In mice, the vaccine was highly immunogenic, eliciting both strong humoral and cellular immune responses. Nasal application resulted in high secretory immunoglobulin A (sIgA) production, which was detectable on the mucosal surface of the urogenital tract. Finally, it conveyed protection, as shown by a significant reduction of bacterial load in a mouse model of ExPEC peritonitis. This study provides evidence that a novel vaccine design encompassing distinct epitopes of virulence-associated ExPEC proteins may represent a means for providing a protective and pathogen-specific vaccine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20498257      PMCID: PMC2916271          DOI: 10.1128/IAI.00174-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Characterization of a putative virulence island in the chromosome of uropathogenic Escherichia coli possessing a gene encoding a uropathogenic-specific protein.

Authors:  H Kurazono; S Yamamoto; M Nakano; G B Nair; A Terai; W Chaicumpa; H Hayashi
Journal:  Microb Pathog       Date:  2000-03       Impact factor: 3.738

2.  Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC.

Authors:  T A Russo; J R Johnson
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

Review 3.  Addressing the challenge of extended-spectrum beta-lactamases.

Authors:  Jean-Ralph Zahar; Olivier Lortholary; Claude Martin; Gilles Potel; Patrick Plesiat; Patrice Nordmann
Journal:  Curr Opin Investig Drugs       Date:  2009-02

4.  Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.

Authors:  S Langermann; R Möllby; J E Burlein; S R Palaszynski; C G Auguste; A DeFusco; R Strouse; M A Schenerman; S J Hultgren; J S Pinkner; J Winberg; L Guldevall; M Söderhäll; K Ishikawa; S Normark; S Koenig
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

5.  Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multi-component fusion protein MultiHIV--study in domestic pigs.

Authors:  Tarmo Mölder; Maarja Adojaan; Katrin Kaldma; Mart Ustav; Rein Sikut
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

6.  Antigen-specific responses accelerate bacterial clearance in the bladder.

Authors:  Praveen Thumbikat; Carl Waltenbaugh; Anthony J Schaeffer; David J Klumpp
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

7.  Aspects of genome plasticity in pathogenic Escherichia coli.

Authors:  Martina Bielaszewska; Ulrich Dobrindt; Julia Gärtner; Inka Gallitz; Jörg Hacker; Helge Karch; Daniel Müller; Sören Schubert; M Alexander Schmidt; Liisa Johanna Sorsa; Jaroslaw Zdziarski
Journal:  Int J Med Microbiol       Date:  2007-04-25       Impact factor: 3.473

8.  The Vienna RNA websuite.

Authors:  Andreas R Gruber; Ronny Lorenz; Stephan H Bernhart; Richard Neuböck; Ivo L Hofacker
Journal:  Nucleic Acids Res       Date:  2008-04-19       Impact factor: 16.971

9.  Mucosal immunization with iron receptor antigens protects against urinary tract infection.

Authors:  Christopher J Alteri; Erin C Hagan; Kelsey E Sivick; Sara N Smith; Harry L T Mobley
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

10.  A novel DNA vaccine containing multiple TB-specific epitopes casted in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge.

Authors:  Haifeng Gao; Yan Yue; Linkun Hu; Wei Xu; Sidong Xiong
Journal:  Vaccine       Date:  2009-07-16       Impact factor: 3.641

View more
  30 in total

Review 1.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

Review 2.  Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?

Authors:  Alejandro Beceiro; María Tomás; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

3.  Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains.

Authors:  Jonathan Messika; Fatma Magdoud; Olivier Clermont; Dimitri Margetis; Stéphane Gaudry; Damien Roux; Catherine Branger; Didier Dreyfuss; Erick Denamur; Jean-Damien Ricard
Journal:  Intensive Care Med       Date:  2012-09-28       Impact factor: 17.440

Review 4.  From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections.

Authors:  Jennifer A Silverman; Henry L Schreiber; Thomas M Hooton; Scott J Hultgren
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

5.  Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia.

Authors:  Agnès Lefort; Xavière Panhard; Olivier Clermont; Paul-Louis Woerther; Catherine Branger; France Mentré; Bruno Fantin; Michel Wolff; Erick Denamur
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

Review 6.  Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 7.  Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Authors:  Ariel R Brumbaugh; Harry L T Mobley
Journal:  Expert Rev Vaccines       Date:  2012-06       Impact factor: 5.217

8.  Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection.

Authors:  Ariel R Brumbaugh; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2013-06-24       Impact factor: 3.441

9.  Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany.

Authors:  David A Rasko; Dale R Webster; Jason W Sahl; Ali Bashir; Nadia Boisen; Flemming Scheutz; Ellen E Paxinos; Robert Sebra; Chen-Shan Chin; Dimitris Iliopoulos; Aaron Klammer; Paul Peluso; Lawrence Lee; Andrey O Kislyuk; James Bullard; Andrew Kasarskis; Susanna Wang; John Eid; David Rank; Julia C Redman; Susan R Steyert; Jakob Frimodt-Møller; Carsten Struve; Andreas M Petersen; Karen A Krogfelt; James P Nataro; Eric E Schadt; Matthew K Waldor
Journal:  N Engl J Med       Date:  2011-07-27       Impact factor: 91.245

10.  Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis.

Authors:  Melha Mellata; Natalie M Mitchell; Florian Schödel; Roy Curtiss; Gerald B Pier
Journal:  Vaccine       Date:  2015-12-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.